SecBot SecBot
SECBOTREPLAY Home › Report › TBPH

TBPH · Theravance Biopharma reported Q2 2026 earnings with no analyst…

Theravance Biopharma, Inc. · 8-K filed Aug 10, 2026 at 08:35 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 10, 2026 at 08:35 ET

Theravance Biopharma reported Q2 2026 earnings with no analyst consensus provided for the current period. The filing is dominated by the pending acquisition by Zymeworks for $17.00 per share in cash plus a CVR, expected to close in H2 2026. YUPELRI collaboration revenue grew 11% YoY to $20.7M, and the company posted a GAAP net loss of $5.9M vs net income of $54.8M in Q2 2025 (which included a $75.1M one-time gain). Non-GAAP net income from operations was $9.5M vs a loss of $4.2M a year ago.

  • Pending acquisition by Zymeworks at $17.00 per share in cash plus a CVR entitling shareholders to 80% of future ampreloxetine monetization proceeds over 10 years.
  • YUPELRI collaboration revenue increased 11% year-over-year to $20.7 million in Q2 2026.
  • GAAP net loss of $5.9 million in Q2 2026 vs net income of $54.8 million in Q2 2025 (which included a $75.1M net gain on realized royalty assets).
  • Non-GAAP net income from operations was $9.5 million in Q2 2026 vs a non-GAAP net loss of $4.2 million in Q2 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access